Equities Analysts Offer Predictions for TSE:FRX Q1 Earnings

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Fennec to ($0.03) from $0.10 and lowered FY2026 EPS to $0.43, signaling weaker near-term profitability expectations.
• Despite near-term revisions, B. Riley upgraded the stock to a Strong Buy and HC Wainwright projects substantial expansion into FY2027 (firm-level EPS of $1.33), supported by the company reporting record PEDMARK sales in 2025.
• Director Rostislav Christov Raykov bought 15,598 shares at C$3.37 and company insiders now own 16.20% of the stock, indicating notable insider conviction.

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, down from their prior forecast of $0.10. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.43 EPS, Q1 2027 earnings at $0.24 EPS and Q2 2027 earnings at $0.31 EPS.

Separately, B. Riley Financial raised Fennec Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Strong Buy".

Fennec Pharmaceuticals Price Performance

FRX opened at C$8.33 on Wednesday. Fennec Pharmaceuticals has a fifty-two week low of C$7.02 and a fifty-two week high of C$13.83. The firm has a market capitalization of C$284.58 million, a PE ratio of -23.80 and a beta of 3.01. The company's 50-day moving average is C$10.53 and its 200 day moving average is C$11.11.

Insiders Place Their Bets

In other news, Director Rostislav Christov Raykov bought 15,598 shares of the stock in a transaction dated Monday, February 2nd. The stock was bought at an average price of C$3.37 per share, for a total transaction of C$52,565.26. Following the completion of the acquisition, the director directly owned 2,719,643 shares in the company, valued at approximately C$9,165,196.91. This trade represents a 0.58% increase in their position. Company insiders own 16.20% of the company's stock.

Fennec Pharmaceuticals News Roundup

Here are the key news stories impacting Fennec Pharmaceuticals this week:

• Positive Sentiment: Company reported record PEDMARK sales in 2025 and described building clinical and commercial momentum, which supports revenue growth expectations and longer-term upside for the stock. Fennec Posts Record PEDMARK Sales in 2025
• Positive Sentiment: HC Wainwright issued a bullish FY2027 outlook (firm-level FY2027 EPS of $1.33 and multiple positive quarterly forecasts for 2027), implying substantial earnings expansion potential beyond 2026. This supports a constructive long-term thesis if execution and sales momentum continue. HC Wainwright Estimates (MarketBeat)
• Negative Sentiment: HC Wainwright cut several near-term estimates — notably Q1 & Q2 2026 and lowered FY2026 EPS from $0.88 to $0.43 — signaling weaker near-term profitability expectations; those revisions typically pressure the stock as they reduce near-term earnings visibility. HC Wainwright Cuts (MarketBeat)
• Negative Sentiment: Company disclosed inducement option grants (377,500 ISOs) approved by the compensation committee, which can lead to potential dilution and is often viewed as a mild headwind to share value until exercised or offset. Fennec Announces Inducement Grants

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.